Protection of clinical trial subjects in countries outside the EU
In this briefing paper, Wemos and SOMO call upon the European Parliament, the European Commission and the European Medicines Agency to take measures at the following three levels: 1) Vigorously pursue the integration of ethical principles into EMA procedures, 2) Increase transparency in clinical trials outside the EU and 3) Strengthen capacity in low and middle income countries.
Protection of clinical trial subjects in countries outside the EU
| Type | Paper |
|---|---|
| Date | September 2011 |
| dossier |
Pharmaceutical Industry
|
| Responsible organisation |
SOMO
Wemos |
